Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection.
References:
[1]. Wang Changyi, et al. Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients. World Intellectual Property Organization, WO2018035001 A1. 2018-02-22. [2]. Semzuvolimab. IMGT/mAb-DB.